Literature DB >> 2039832

Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction.

M Lawler1, P Humphries, S R McCann.   

Abstract

The influence of mixed hematopoietic chimerism (MC) after allogeneic bone marrow transplantation remains unknown. Increasingly sensitive detection methods have shown that MC occurs frequently. We report a highly sensitive novel method to assess MC based on the polymerase chain reaction (PCR). Simple dinucleotide repeat sequences called microsatellites have been found to vary in their repeat number between individuals. We use this variation to type donor-recipient pairs following allogeneic BMT. A panel of seven microsatellites was used to distinguish between donor and recipient cells of 32 transplants. Informative microsatellites were subsequently used to assess MC after BMT in this group of patients. Seventeen of the 32 transplants involved a donor of opposite sex; hence, cytogenetics and Y chromosome-specific PCR were also used as an index of chimerism in these patients. MC was detected in bone marrow aspirates and peripheral blood in 18 of 32 patients (56%) by PCR. In several cases, only stored slide material was available for analysis but PCR of microsatellites or Y chromosomal material could be used successfully to assess the origin of cells in this archival material. Cytogenetic analysis was possible in 17 patients and MC was detected in three patients. Twelve patients received T-cell-depleted marrow and showed a high incidence of MC as revealed by PCR (greater than 80%). Twenty patients received unmanipulated marrow, and while the incidence of MC was lower (44%), this was a high percentage when compared with other studies. Once MC was detected, the percentages of recipient cells tended to increase. However, in patients exhibiting MC who subsequently relapsed, this increase was relatively sudden. The overall level of recipient cells in the group of MC patients who subsequently relapsed was higher than in those who exhibited stable MC. Thus, while the occurrence of MC was not indicative of a poor prognosis per se, sudden increases in the proportions of recipient cells may be a prelude to graft rejection or relapse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039832

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  The scope of quantitative polymerase chain reaction assays in clinical molecular pathology.

Authors:  R D Malcomson; C T McCullough; D J Bruce; D J Harrison
Journal:  Clin Mol Pathol       Date:  1995-08

3.  Concordance of genotypes in pre- and post-lung transplantation DNA samples.

Authors:  Dawn L DeMeo; John J Reilly; Leo C Ginns; Jody S Sylvia; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-30       Impact factor: 6.914

4.  Evaluation of mixed chimerism by two-step polymerase chain reaction amplification of hypervariable region MCT118 after allogeneic bone marrow transplantation.

Authors:  J Tanaka; M Kasai; M Imamura; T Higa; S Kobayashi; S Hashino; K Sakurada; T Miyazaki
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

5.  Monitoring of hematopoietic chimerism by real-time quantitative PCR of micro insertions/deletions in samples with low DNA quantities.

Authors:  Christian Bach; Elmira Tomova; Katja Goldmann; Volker Weisbach; Wolf Roesler; Andreas Mackensen; Julia Winkler; Bernd M Spriewald
Journal:  Transfus Med Hemother       Date:  2014-12-22       Impact factor: 3.747

6.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

7.  Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.

Authors:  B J Boughton; A W Simpson; T A Phaure; C Beatty
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

8.  Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.

Authors:  S J Park; W S Min; I H Yang; H J Kim; C K Min; H S Eom; D W Kim; C W Han; J W Lee; C C Kim
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

9.  Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies.

Authors:  Mahmoud Aljurf; Hala Abalkhail; Amal Alseraihy; Said Y Mohamed; Mouhab Ayas; Fahad Alsharif; Hazza Alzahrani; Abdullah Al-Jefri; Ghuzayel Aldawsari; Ali Al-Ahmari; Asim F Belgaumi; Claudia Ulrike Walter; Hassan El-Solh; Walid Rasheed; Maher Albitar
Journal:  Biotechnol Res Int       Date:  2016-02-23

10.  Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation.

Authors:  Tanja Stahl; Caroline Rothe; Manja U Böhme; Aloisa Kohl; Nicolaus Kröger; Boris Fehse
Journal:  Int J Mol Sci       Date:  2016-09-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.